BlackRock’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-9,610,239
| Closed | -$227M | – | 5427 |
|
|
2023
Q4 | $227M | Buy |
9,610,239
+1,818,243
| +23% | +$32.4M | 0.01% | 1570 |
|
|
2023
Q3 | $116M | Buy |
7,791,996
+287,326
| +4% | +$3.81M | ﹤0.01% | 1905 |
|
|
2023
Q2 | $82.2M | Buy |
7,504,670
+4,854,593
| +183% | +$45.2M | ﹤0.01% | 2177 |
|
|
2023
Q1 | $23.1M | Buy |
2,650,077
+634,577
| +31% | +$5.08M | ﹤0.01% | 2904 |
|
|
2022
Q4 | $12.6M | Buy |
2,015,500
+70,850
| +4% | +$269K | ﹤0.01% | 3280 |
|
|
2022
Q3 | $6.81M | Sell |
1,944,650
-8,219
| -0.4% | -$29.5K | ﹤0.01% | 3618 |
|
|
2022
Q2 | $5.76M | Sell |
1,952,869
-3,513,340
| -64% | -$8.39M | ﹤0.01% | 3758 |
|
|
2022
Q1 | $17M | Buy |
5,466,209
+142,081
| +3% | +$447K | ﹤0.01% | 3278 |
|
|
2021
Q4 | $18M | Buy |
5,324,128
+118,650
| +2% | +$450K | ﹤0.01% | 3335 |
|
|
2021
Q3 | $19M | Sell |
5,205,478
-226,192
| -4% | -$891K | ﹤0.01% | 3311 |
|
|
2021
Q2 | $23.7M | Sell |
5,431,670
-526,818
| -9% | -$2.34M | ﹤0.01% | 3200 |
|
|
2021
Q1 | $27.1M | Buy |
5,958,488
+572,244
| +11% | +$3.08M | ﹤0.01% | 3015 |
|
|
2020
Q4 | $30.9M | Buy |
5,386,244
+255,336
| +5% | +$1.93M | ﹤0.01% | 2773 |
|
|
2020
Q3 | $37.1M | Sell |
5,130,908
-485,654
| -9% | -$2.6M | ﹤0.01% | 2468 |
|
|
2020
Q2 | $19.6M | Buy |
5,616,562
+84,974
| +2% | +$245K | ﹤0.01% | 2811 |
|
|
2020
Q1 | $8.19M | Sell |
5,531,588
-58,263
| -1% | -$97.8K | ﹤0.01% | 3100 |
|
|
2019
Q4 | $11M | Sell |
5,589,851
-38,388
| -0.7% | -$144K | ﹤0.01% | 3201 |
|
|
2019
Q3 | $28.8M | Buy |
5,628,239
+97,547
| +2% | +$591K | ﹤0.01% | 2609 |
|
|
2019
Q2 | $39.6M | Buy |
5,530,692
+493,662
| +10% | +$5.59M | ﹤0.01% | 2460 |
|
|
2019
Q1 | $66.9M | Sell |
5,037,030
-124,551
| -2% | -$1.32M | ﹤0.01% | 2118 |
|
|
2018
Q4 | $40.6M | Buy |
5,161,581
+722,753
| +16% | +$6.88M | ﹤0.01% | 2359 |
|
|
2018
Q3 | $49.2M | Buy |
4,438,828
+384,543
| +9% | +$4.78M | ﹤0.01% | 2384 |
|
|
2018
Q2 | $54.4M | Buy |
4,054,285
+2,885,082
| +247% | +$36.1M | ﹤0.01% | 2308 |
|
|
2018
Q1 | $15.2M | Buy |
1,169,203
+478,524
| +69% | +$5.95M | ﹤0.01% | 2910 |
|
|
2017
Q4 | $6.35M | Buy |
690,679
+77,459
| +13% | +$662K | ﹤0.01% | 3351 |
|
|
2017
Q3 | $4.94M | Buy |
613,220
+431,896
| +238% | +$2.92M | ﹤0.01% | 3469 |
|
|
2017
Q2 | $1.04M | Buy |
181,324
+61,979
| +52% | +$264K | ﹤0.01% | 3840 |
|
|
2017
Q1 | $513K | Buy |
+119,345
| New | +$342K | ﹤0.01% | 3952 |
|
Other funds holding CBAY
BlackRock's CBAY Position: Q1 2024 in Review
BlackRock sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 9,610,239 shares — an estimated $227M sold.
BlackRock first reported a position in CBAY in Q1 2017 and held it in 28 quarters. The position peaked at $227M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- BlackRock reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- BlackRock sold 9,610,239 Cymabay Therapeutics shares in Q1 2024, an estimated $227M.
- BlackRock first reported a position in Cymabay Therapeutics in Q1 2017 and held it in 28 quarters.
- BlackRock's Cymabay Therapeutics position peaked at $227M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.